# Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

> **NCT02874794** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 465 (actual)

## Conditions studied

- Heart Failure and Reduced Ejection Fraction

## Interventions

- **DRUG:** LCZ696 (sacubitril/valsartan)
- **DRUG:** Enalapril
- **DRUG:** Placebo of Enalapril
- **DRUG:** Placebo of LCZ696

## Key facts

- **NCT ID:** NCT02874794
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-17
- **Primary completion:** 2018-12-13
- **Final completion:** 2019-01-26
- **Target enrollment:** 465 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02874794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02874794, "Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02874794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*